Korro Bio (NASDAQ:KRRO) Now Covered by Analysts at Oppenheimer

Oppenheimer began coverage on shares of Korro Bio (NASDAQ:KRRO) in a report issued on Friday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $155.00 price target on the stock. Oppenheimer’s price objective would indicate a potential upside of 312.01% from the company’s current price.

A number of other research firms also recently weighed in on KRRO. HC Wainwright restated a “buy” rating and issued a $115.00 price objective on shares of Korro Bio in a report on Friday, November 22nd. Royal Bank of Canada raised their price objective on Korro Bio from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Monday, October 21st. William Blair reiterated an “outperform” rating on shares of Korro Bio in a report on Wednesday, November 13th. Finally, Raymond James initiated coverage on shares of Korro Bio in a report on Monday, October 21st. They set a “strong-buy” rating and a $153.00 price target for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $144.00.

Korro Bio Trading Down 2.0 %

Korro Bio stock opened at $37.62 on Friday. The stock has a 50-day moving average price of $48.80 and a two-hundred day moving average price of $45.92. Korro Bio has a 12 month low of $30.00 and a 12 month high of $98.00.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Tuesday, November 12th. The company reported ($2.26) EPS for the quarter, topping the consensus estimate of ($2.55) by $0.29. As a group, equities analysts predict that Korro Bio will post -9.7 earnings per share for the current fiscal year.

Insider Transactions at Korro Bio

In other Korro Bio news, CFO Vineet Agarwal sold 800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $70.00, for a total value of $56,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Korro Bio

A number of large investors have recently modified their holdings of the company. Point72 Asset Management L.P. increased its holdings in Korro Bio by 71.6% during the 2nd quarter. Point72 Asset Management L.P. now owns 456,085 shares of the company’s stock worth $15,448,000 after purchasing an additional 190,259 shares in the last quarter. Driehaus Capital Management LLC bought a new stake in Korro Bio during the second quarter worth $3,958,000. Tri Locum Partners LP bought a new stake in Korro Bio during the second quarter worth $2,419,000. Millennium Management LLC raised its position in Korro Bio by 38.3% in the 2nd quarter. Millennium Management LLC now owns 84,201 shares of the company’s stock valued at $2,852,000 after buying an additional 23,307 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Korro Bio during the 2nd quarter valued at $649,000. 13.18% of the stock is currently owned by institutional investors.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).